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Abstract
Aim: To assess plasma zinc and copper concentration in individuals with Asperger’s Syndrome, Pervasive Developmental Disorder-
Not Otherwise Specified (PDD-NOS) and autistic disorder, and to analyze the efficacy of zinc therapy on the normalization of zinc and 
copper levels and symptom severity in these disorders.
Subjects and methods: Plasma from 79 autistic individuals, 52 individuals with PDD-NOS, 21 individuals with Asperger’s Syndrome 
(all meeting DSM-IV diagnostic criteria), and 18 age and gender similar neurotypical controls, were tested for plasma zinc and copper 
using inductively-coupled plasma-mass spectrometry.
Results: Autistic and PDD-NOS individuals had significantly elevated plasma levels of copper. None of the groups (autism, Asperger’s 
or PDD-NOS) had significantly lower plasma zinc concentrations.
Post zinc and B-6 therapy, individuals with autism and PDD-NOS had significantly lower levels of copper, but individuals with Asperger’s 
did not have significantly lower copper. Individuals with autism, PDD-NOS and Asperger’s all had significantly higher zinc levels.
Severity of symptoms decreased in autistic individuals following zinc and B-6 therapy with respect to awareness, receptive language, 
focus and attention, hyperactivity, tip toeing, eye contact, sound sensitivity, tactile sensitivity and seizures. None of the measured 
symptoms worsened after therapy. None of the symptoms in the Asperger’s patients improved after therapy.
Discussion: These results suggest an association between copper and zinc plasma levels and individuals with autism, PDD-NOS and 
Asperger’s Syndrome. The data also indicates that copper levels normalize (decrease to levels of controls) in individuals with autism 
and PDD-NOS, but not in individuals with Asperger’s. These same Asperger’s patients do not improve with respect to symptoms after 
therapy, whereas many symptoms improved in the autism group. This may indicate an association between copper levels and symptom 
severity.
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Introduction
The  pervasive  developmental  disorders,  or  autism 
spectrum disorders (ASD), range from a severe form, 
called autistic disorder, to a milder form, Asperger 
syndrome. If a child has symptoms of either of these 
disorders, but does not meet the specific criteria for 
either, the diagnosis is called pervasive developmen-
tal  disorder  not  otherwise  specified  (PDD-NOS). 
Other rare, very severe disorders that are included in 
the autism spectrum disorders are Rett syndrome and 
childhood disintegrative disorder.1
ASD is a complex, behaviorally defined neurode-
velopmental  group  of  disorders  characterized  by 
social deficits, language impairments, and repetitive 
behaviors. There has been a dramatic increase in the 
diagnosis of ASDs over the past decade.2
The  etiology  of  this  complex  disease  is  highly 
heritable, but likely involves environmental   factors.3 
Twin  studies  demonstrate  concordance  rates  of 
82%–92%  in  monozygotic  twins  and  1%–10% 
  concordance  rate  in  dizygotic  twins.1  Sibling 
  recurrence risk (6%–8%) is 35 times the population 
prevalence.1,4
Genetic analysis suggests that as many as 15 genes 
might be involved in autism spectrum disorders, includ-
ing variants on chromosomes 2q, 7q, 15q, and 17q.5–8
Children with ASD frequently have accompanying 
gastrointestinal, immunological, or nonspecific neu-
rological symptoms.9–15
Zinc has a unique and extensive role in biological 
processes.  Since  the  discovery  of  this  element  as 
an essential nutrient for living organisms,16–18 many 
diverse biochemical roles for it have been identified. 
These  include  roles  in  enzyme  function,19  nucleic 
acid metabolism,20,21 cell signaling22 and apoptosis.23 
Zinc is essential for physiological processes including 
growth and development,24 lipid metabolism,25 brain 
and immune function.24,26
Dietary  factors  that  reduce  the  availability  of 
zinc are the most common cause of zinc deficiency. 
However, inherited defects can also result in reduced 
zinc. Both nutritional and inherited zinc deficiency 
produce  similar  symptoms,  such  as  dermatitis, 
diarrhea, alopecia and loss of appetite.27 With more 
prolonged  deficiency  causing  growth  impairment 
and neuropsychological changes such as emotional 
instability, irritability and depression.28–31
Deficiency of zinc in man has now been recognized 
to occur not only as a result of nutritional factors, but 
also in various disease states, including malabsorption 
syndromes,  acrodermatitis  enteropathica,  Crohn’s 
disease, alcoholism and cirrhosis of the liver.59,60
Low intracellular zinc has been found to be associ-
ated with DNA damage, oxidative stress, antioxidant 
defenses, and DNA repair,32,33 and zinc may serve as 
an important anti-oxidant.34
Copper (Cu), a trace metal, is also an essential 
element for living cells. It plays an important role 
in  redox  reactions  because  of  its  easy  conversion 
from Cu+ to Cu++. Copper is transported mainly by 
ceruloplasmin, a copper-binding antioxidant protein 
that  is  synthesized  in  several  tissues,  including 
brain.35,36
Copper  levels  are  low  in  Menke’s  kinky  hair 
syndrome,37  malnutrition38  and  Malabsorption.39 
  Elevated copper levels are associated with infections,40 
inflammation,41 trauma,42 Wilson’s disease,43 excessive 
dietary  intake44  systemic  lupus  erythematosus,45  as 
well as autism.46
Because of the potential association between Zn 
and Cu levels and ASD, we tested patients with autism, 
Asperger’s and PDD-NOS for plasma   concentration of 
these elements and then compared the concentrations 
with severity of disease symptoms.
Materials and Methods
Subjects
experimental and control
Plasma from 79 autistic individuals 68 make; mean 
age 11.7 ± 5.62), 52 individuals with PDD-NOS 
(47  male;  mean  age  9.9  ±  7.6),  21  individuals 
with  Asperger’s  Syndrome  (19  male;  mean  age 
14.87  ±  7.87)  (all  meeting  DSM-IV  diagnostic 
  criteria), and 18 age and gender similar neurotypical 
  controls, was obtained from patients presenting at 
the  Health  Research  Institute/Pfeiffer  Treatment 
Center. Most of these individuals meet the DSM-IV 
criteria  and  were  diagnosed  using  The  Autism 
  Diagnostic  Interview-Revised—ADI-R  before 
presenting for treatment at the Pfeiffer Treatment 
Center, Warrenville, Il.*
*The Pfeiffer Treatment Center is a comprehensive treatment and research center, 
specializing in the care of with neurological disorders, including depression.copper and zinc plasma concentration in Asperger’s, PDD-nOS and autism
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Patient  consent  was  obtained  from  all  patients 
involved in this study and this study was approved 
by the IRB of the Health Research Institute/Pfeiffer 
Treatment Center.
Severity of disease
An  autism  questionnaire  was  used  to  evaluate 
symptoms. The questionnaire (Pfeiffer Questionnaire) 
asked parents or caregivers to assess the severity of 
the  following  symptoms:  Awareness,  Expressive 
Language,  Receptive  Language,  (Conversational) 
Pragmatic Language, Focus, Attention, Hyperactivity, 
Impulsivity, Perseveration, Fine Motor Skills, Gross 
Motor  Skills,  Hypotonia  (low  muscle  tone),  Tip 
Toeing,  Rocking/Pacing,  Stimming,  Obsessions/
Fixations,  Eye  Contact,  Sound  Sensitivity,  Light 
Sensitivity, Tactile Sensitivity, Pica/ eats dirt, metal, 
Tics and Seizures. The symptoms were rated on a 
scale of 0–5 (5 being the highest severity) for each of 
these behaviors.
Zn and Anti-Oxidant Therapy
Individuals in this study who presented to the   Pfeiffer 
Treatment  Center  with  depression  (or  anxiety) 
were  tested  for  Zn,  Cu  and  anti-oxidant  levels. 
Based  on  deficiencies,  they  were  then  prescribed 
the appropriate dose of anti-oxidants. Pre-therapy 
patients represent those who were tested when they 
first presented and were not previously taking any 
Zn or anti-  oxidants. Post-Therapy patients received 
anti-oxidant  therapy  (Vitamin  C,  E,  B-6  as  well 
as Magnesium, and   Manganese if warranted), and 
Zn supplementation (as Zn picolinate), daily, for a 
minimum of 8 weeks.
Serum/Plasma
All experimental and control plasmas were treated in 
an identical fashion—refrigerated (4 C) immediately 
after collection and cell/serum separation, then used 
within 4 hours for inductively-coupled plasma-mass 
spectrometry.
Copper and Zinc Serum 
concentration
Copper and zinc plasma concentration was performed 
by  LabCorp,  Inc.  (Naperville,  IL  60563)  using 
inductively-coupled  plasma-mass  spectrometry,  as 
previously described.62
statistics
Inferential  statistics  were  derived  from  t-test  with 
95% confidence intervals.
Results
Plasma from 79 autistic individuals, 52 individuals 
with  PDD-NOS,  21  individuals  with  Asperger’s 
  Syndrome (all meeting DSM-IV diagnostic   criteria), 
and 18 age and gender similar neurotypical   controls, 
were  tested  for  plasma  zinc  and  copper  using 
inductively-coupled plasma-mass spectrometry.
Autistic  and  PDD-NOS  individuals  had  signifi-
cantly elevated plasma levels of copper (P = 0.0133; 
P  =  0.04556,  respectively)  None  of  the  groups 
(autism, Asperger’s or PDD-NOS) had significantly 
lower plasma zinc concentration (Table 1).
Post zinc and B-6 therapy, individuals with autism 
and  PDD-NOS  had  significantly  lower  levels  of 
copper (P = 0.00972; P = 0.04139, respectively), but 
individuals with Asperger’s did not have significantly 
Table 1. Plasma cu (mg/dL), Zn (mg/dL) and cu/Zn in neurotypical controls and Autistic, Asperger’s and PDD-nOS 
Individuals.
Controls Cu Autistic Cu Asperger’s Cu PDD-NOS Cu
Mean 90.42 111.50 101.67 106.81
SD 19.55 27.73 18.87 18.05
SeM 5.64 3.22 4.12 2.5
P = 0.0133 P = 0.16438 P = 0.04556
controls Zn Autistic Zn Asperger’s Zn PDD-NOS Zn
Mean 84.42 78.36 83.1 79.48
SD 24.18 20.32 25.87 22.25
SeM 6.98 2.36 5.64 3.08
P = 0.3541 P = 0.35638 P = 0.17296russo et al
130  Biomarker Insights 2011:6
seizures  (P  =  0.057).  None  of  the  measured 
symptoms  worsened  after  therapy.  None  of  the 
symptoms in the Asperger’s patients improved after 
therapy (Fig. 1).
Discussion
There is much support for the role of GABA in the etiol-
ogy of autism. Alterations in levels of GABA and GABA 
receptors in autistic patients indicate that the GABAer-
gic system, which is responsible for synaptic inhibition 
in the adult brain, may be involved in autism.47–49
Zinc has been found to be associated with GABA 
and  glutamate  regulation,  particularly  through 
anxiolytic  activity,  modulating  GABAergic  inhibi-
tion  and  seizure  susceptibility.50–52  Zinc  deficiency 
has also been found to be associated with GABAergic 
impairment.53
Copper,  on  the  other  hand,  has  been  found  to 
be  a  potent  inhibitor  of  GABA-evoked  responses, 
  particularly in Purkinje cells. Copper toxicity, notably 
in Wilson’s disease, could result, to some extent, from 
chronic GABAA receptor blockade.54 Data strongly 
suggest that Cu and Zn might interact with each other 
with  GABAA  receptor  complex  and  participate  in 
modulation of synaptic transmission.55
Dopamine-β-hydroxylase (DBH) is a neurotrans-
mitter,  synthesizing  enzyme,  which  catalyzes  the 
formation of norepinephrine from dopamine. Copper 
is a co-factor required for this enzyme’s activity.57,58 
Increased norepinephrine levels have been found in 
autistic individuals,56 which, at least in part, could be 
explained by excess copper.
Our study shows that autistic individuals have 
lower levels of zinc and significantly higher   levels 
of copper when compared to neurotypical   controls. 
We suggest that the low zinc and high copper may 
modulate  GABA,  ultimately  causing  a    lowering 
of  transmitter  concentration.  High  copper  may 
also be associated with high norepinephrine found 
in  autistic  children,  and  low  GABA  and  high 
  epinephrine  may,  in  turn,  manifest  as  excitability 
and hyperactivity associated autistic symptoms. To 
evaluate this   relationship, future studies will assess 
more patients with autism and evaluate GABA and 
norepinephrine levels, as they are associated with 
Cu and Zn levels.
Zinc  induces  the  intestinal  synthesis  of  a 
copper-binding  protein’s  such  as  metallothionein. 
Table 2. Plasma cu and Zn concentration (mg/dL), pre 
and post zinc therapy, in autistic, Asperger’s and PDD-
nOS individuals.
Autistic Cu  
pre therapy
Autistic Cu  
post therapy
copper
Mean 111.50 98.78
SD 27.73 24.86
SeM 3.22 3.48
P = 0.00972
PDD-NOS Cu  
pre therapy
PDD-NOS Cu  
post therapy
Mean 106.8 98.09
SD 18.05 20.18
SeM 2.5 3.51
P = 0.04139
Asp Cu  
pre therapy
Asp Cu  
post therapy
Mean 98.82 101.66
SD 21.22 18.87
SeM 5.14 4.11
P = 0.66915
Zinc
Autistic Zn  
pre therapy
Autistic Zn  
post therapy
Mean 78.36 102.58
SD 20.32 28.13
SeM 2.36 3.94
P = 0.0001
PDD-NOS Zn  
pre therapy
PDD-NOS Zn  
post therapy
Mean 79.48 102.06
SD 22.25 23.71
SeM 3.08 4.19
P = 0.0003
Asp Zn  
pre therapy
Asp Zn  
post therapy
Mean 83.09 112
SD 25.87 22.63
SeM 5.64 5.48
P = 0.00078
lower copper (P = 0.66915). Individuals with autism, 
PDD-NOS and Asperger’s all had significantly higher 
zinc levels (Table 2).
Severity  of  symptoms  decreased  in  autistic 
individuals  following  zinc  and  B-6  therapy  with 
respect  to  awareness  (P  =  0.039),  receptive  lan-
guage (P = 0.014), focus and attention (P = 0.011), 
Hyperactivity (P = 0.002), Tip Toeing (P = 0.002), 
Eye  Contact  (P  =  0.085),  Sound  Sensitivity 
(P  =  0.098), Tactile  Sensitivity  (P  =  0.012)  and copper and zinc plasma concentration in Asperger’s, PDD-nOS and autism
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Metallothionein traps copper within intestinal cells and 
prevents its systemic absorption.61 Our data suggest an 
association between copper and zinc plasma levels and 
individuals with autism, PDD-NOS and Asperger’s 
Syndrome. We report that copper levels normalize 
(decrease to levels of controls) in individuals with 
autism and PDD-NOS, but not in individuals with 
Asperger’s. These same Asperger’s patients do not 
improve  with  respect  to  symptoms  after  therapy, 
whereas severity of symptoms (awareness, receptive 
language, focus and attention, hyperactivity, tip toeing, 
eye contact, sound sensitivity, tactile sensitivity and 
seizures) decreased in autistic individuals following 
zinc and B-6 therapy.
We do not know why copper doesn’t normalize 
after zinc therapy in Asperger’s patients but suggest 
that since symptom severity of these patients remains 
high, high copper levels are most likely associated 
with symptom severity.
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